We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Fabry Disease is a rare genetic disorder caused by the deficiency of an enzyme called alpha-galactosidase A, leading to the buildup of a fatty substance in various organs, particularly affecting the kidneys and heart. Patients may experience severe renal impairment or end-stage renal disease, often requiring hemodialysis.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.